Retinopathy

Exonate Appoints Dr Rafiq Hasan as Non-Executive Director

Retrieved on: 
星期二, 五月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, Patient, Diabetic retinopathy, Complement, Therapy, Senior, SRPK1, Eye disease, Eye, Injection, Bayer, Retinopathy, Pharmaceutical industry

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.

Key Points: 
  • Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.
  • Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.
  • In addition to his role at Complement, Rafiq holds Board and advisory roles at Oxular and BioGeneration Ventures.
  • Catherine Beech, CEO, Exonate, said: “We’re pleased to welcome Dr Hasan to Exonate’s Board as Non-Executive Director.

Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System

Retrieved on: 
星期一, 五月 6, 2024
Technology, FDA, Baby, Maternity, Public Relations, Investor Relations, Communications, Audio, Video, General Health, Consumer, Health, Consumer Electronics, NICU, Humidity, Hospital, Skin, OTC, Depression, Oxygen saturation (medicine), PR, Parent, Infant, Motion, Skin temperature, Perfusion, Science, Incidence, Patient, QHD, Caregiver, Multimedia, MASI, Child, Diagnosis, Retinopathy, Temperature, Medical device

Alongside the FDA clearance, Masimo will make Stork’s new alarm features available to all existing and new Stork users through the Masimo Stork App, in an update scheduled to be released this summer.

Key Points: 
  • Alongside the FDA clearance, Masimo will make Stork’s new alarm features available to all existing and new Stork users through the Masimo Stork App, in an update scheduled to be released this summer.
  • Masimo Stork is 510(k) cleared for OTC use as a wearable device intended for the monitoring of multiple physiological parameters.
  • Masimo Stork is not intended to replace the monitoring, diagnosis, or treatment provided by a physician or healthcare provider.
  • Masimo Stork is not intended for use with infants and neonates previously diagnosed with cardiovascular or respiratory disease or conditions.

Prevent Blindness Announces Recipients of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and the Rising Visionary Award

Retrieved on: 
星期一, 四月 29, 2024
Education, Public, AOP, Religion, Achievement Medal, Health equity, Public health, Woman, Essay, School, Premature, All but dissertation, Mentorship, Empowerment, Doctor of Philosophy, Visual impairment, Life, OD, University college, Primary health care, Retinopathy, Culture, Psychology, Patient, Nursing, DPA, Retinoblastoma

CHICAGO, April 29, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety organization, has announced the recipient of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health as Mission for Vision (MFV). Erica Shelton, OD, MS, FAAO, Clinical Instructor and PhD Candidate, The Ohio State University College of Optometry, has been named as the recipient of the fifth annual "Rising Visionary Award." Both award recipients will present at the 13th Annual Prevent Blindness Focus on Eye Health Summit, to be held as a virtual interactive event on July 10-11, 2024.

Key Points: 
  • "Prevent Blindness congratulates Mission for Vision and Dr. Erica Shelton as recipients of two of our most prestigious awards," said Jeff Todd, president and CEO of Prevent Blindness.
  • These award recipients were chosen by a volunteer selection committee, consisting of leading professionals in ophthalmology, optometry, advocacy, public health, and scientific communities.
  • The award serves as a living memorial to Jenny Pomeroy, who served as the CEO of Prevent Blindness Georgia from 1996 until 2013 and was a tireless champion of public health and vision advocacy.
  • For more information on the Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health and the Rising Visionary Award, please visit PreventBlindness.org .

JDRF Celebrates Research Award Winners and Recognizes Type 1 Diabetes Research Leaders

Retrieved on: 
星期四, 四月 18, 2024
Consensus, University, Type 1 diabetes, Diabetes, Person, Risk, Food, Research, JDRF, Immunotherapy, Endocrinology, Retinopathy, Disease, Indiana University, Medicine, Metabolism, Clinical trial, Petah Tikva, Pediatrics, AID, Medical Center, Pediatric endocrinology, Inborn errors of metabolism, Quality of life, Division, Growth, Pharmaceutical industry

NEW YORK, April 18, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding leaders in T1D research whose impact has pushed JDRF's mission forward.

Key Points: 
  • NEW YORK, April 18, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding leaders in T1D research whose impact has pushed JDRF's mission forward.
  • She began her career with a JDRF career development award to support one of her first research projects on insulin pump therapy in very young children with diabetes.
  • The award recognizes leaders and innovators of outstanding clinical and translational T1D research.
  • JDRF Research award recipients were recognized at a ceremony in New York City earlier in April 2024.

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
星期三, 三月 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

Retrieved on: 
星期二, 三月 5, 2024
Health, Diabetes, Clinical Trials, Research, Science, Optical, Biotechnology, Therapy, ARVO, Growth, Eye, Diabetic retinopathy, Safety, Alternative splicing, VEGF, Patient, Retinopathy, Phase, Trial of the century

These data demonstrate the safety and tolerability of EXN407, as well as clear indications of biological activity, positioning it well for further development as the first topical treatment for retinal vascular diseases such as diabetic retinopathy and diabetic macular oedema.

Key Points: 
  • These data demonstrate the safety and tolerability of EXN407, as well as clear indications of biological activity, positioning it well for further development as the first topical treatment for retinal vascular diseases such as diabetic retinopathy and diabetic macular oedema.
  • Exonate is now planning to progress EXN407 to the CLEAR-DM (Clinical Evaluation of a New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema) Phase IIb clinical trial.
  • The mild NPDR/DME (NCT04565756) clinical study assessed the safety, tolerability and signals of biological response to EXN407 monotherapy in a double-masked, placebo-controlled Phase Ib/IIa dose-ranging clinical trial in treatment-naïve patients with mild/moderate non-proliferative diabetic retinopathy (NPDR) and mild diabetic macular oedema.
  • “The results suggest that topical ocular EXN407 may provide clinical benefit and substantially reduce the injection burden for patients with diabetic eye disease.

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
星期三, 二月 21, 2024
Education, Medical director, Medical statistics, Parent, Infant, Pregnancy, University, Organization, Retinopathy, Diagnosis, Gestational age, Head, Social media, Section, Mental health, MBA, Associate professor, MSC, Initiative, Doctor of Psychology, Distribution, Partnership, FACS, National Eye Institute, Ear, University of Illinois Urbana-Champaign, Paratriathlon, ROP, Visual impairment, Safety, Division, MD, Visual Science, Diversity, Patient, Nursing

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

Richard F. Spaide, MD of the Vitreous Retina Macula Consultants of New York Awarded the Arnall Patz Medal by the Macula Society

Retrieved on: 
星期二, 二月 20, 2024
Research, MD, Consultant, Premature, Retinopathy, Annual general meeting, Arnall Patz, Book

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.
  • Dr. Spaide was selected as the honoree of the Arnall Patz Medal by the awards committee of The Macula Society.
  • The Macula Society is the preeminent organization for specialists in the field of macula and retinal diseases.
  • The Arnall Patz Medal is awarded to those who have made outstanding contributions to the understanding of retinal vascular diseases in honor of ophthalmologist Arnall Patz, who is known for his landmark work on retinopathy of prematurity.

Stiffening of retinal blood vessels threatens vision in diabetes

Retrieved on: 
星期二, 十一月 21, 2023
American Diabetes Association, Associate, Vision, UCLA, Capillary, Risk, DR, Research, Physics, Diabetic retinopathy, Paratriathlon, Blood, UC, Mouse, Health, MD, Doheny Eye Institute, Retinopathy, Patient, Retina, University of California, Irvine, Pharmaceutical industry

With the global surge in diabetes cases, the risk of diabetic retinopathy (DR), a vision-threatening complication affecting nearly 40% of all individuals with diabetes, has also escalated significantly.

Key Points: 
  • With the global surge in diabetes cases, the risk of diabetic retinopathy (DR), a vision-threatening complication affecting nearly 40% of all individuals with diabetes, has also escalated significantly.
  • Late-stage DR, characterized by multiplication and leakiness of smaller blood vessels (capillaries) in the retina, often leads to vision loss.
  • That diabetes causes stiffening of large blood vessels is already known.
  • "If larger blood vessels can become stiffer in diabetes, perhaps so could the smaller retinal capillaries", reckoned Kaustabh Ghosh, senior author of the study and Associate Professor of Ophthalmology at UCLA and Doheny Eye Institute.

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Retrieved on: 
星期一, 十二月 18, 2023
Health, FDA, Parenting, Medical Devices, Baby, Maternity, Hospitals, Health Technology, Consumer, PR, Multimedia, Stork, Loma Linda University, Research, NICU, Parent, Hospital, Incidence, Pulse, Pediatrics, Hospital medicine, Motion, Skin temperature, Temperature, MASI, Retinopathy, QHD, Oxygen saturation (medicine), Extremis, Perfusion, ARMS, Patient, Safety, Vital signs, Skin, Child, Pharmaceutical industry

Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.
  • Leveraging the same Masimo sensor technology that monitors more than 10 million babies in hospitals every year, Stork provides continuous, accurate monitoring of a baby’s health.
  • In addition, Stork alerts parents if their baby turns over and is sleeping face down, which can be dangerous for babies.
  • For prescription use, Masimo Stork is 510(k) cleared for the following intended use: Masimo Stork is a wearable device intended for the monitoring of multiple physiological parameters.